Clinical trials: Intermediate Risk Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML)
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR<0.05) AML (FLT3…
- Trial name
- NCT03512197
- Testing
- Midostaurin, Chemotherapy
- Where
- 133 sites in United States, Argentina and 18 more
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
AML
Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML
The goal of this study is to evaluate the efficacy and safety of a conditioning regimen of Mitoxantrone Hydrochloride Liposome in combination with Bu/Cy (M+Bu/Cy) on acute myeloid leukaemia (AML) patients with…
- Trial name
- NCT06758726
- Testing
- Mitoxantrone Hydrochloride Liposome combined with BU/Cy
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitoxantrone, etoposide, and cytarabine, work in different ways to stop the…
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01127009
- Testing
- bortezomib, mitoxantrone hydrochloride, etoposide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Myeloid Leukemia, Minimal Residual Disease Negativity
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
This phase II trial studies how well autologous stem cell transplant works in treating patients with favorable or intermediate risk, minimal residual disease (MRD)-negative, acute myeloid leukemia.
- Trial name
- NCT03515707
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Etoposide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myeloid, Acute
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion…
- Trial name
- NCT03926624
- Testing
- DFP-10917, Cytarabine, Azacitidine
- Where
- 39 sites in United States
- Volunteers
- 167 people
- Sponsor
- Delta-Fly Pharma, Inc.
Acute Myeloid Leukemia
Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4
Purpose : The main objective of this study is to assess the efficacy and tolerance of the addition of repeated doses of low doses (3mg/m2) of Gemtuzumab Ozogamicin (GO) in addition with standard doses of Ara-C in previously…
- Trial name
- ALFA1401 (NCT02473146)
- Testing
- Gemtuzumab ozogamicin (GO)
- Where
- 21 sites in France
- Volunteers
- 225 people
- Sponsor
- Versailles Hospital
Acute Myeloid Leukemia
HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk
Patients with de novo AML enrolled in the study. Patient who has a HLA-identical donor is assigned to receive NST therapy with GVHD prophylaxis and who has no HLA-identical donor is assigned to receive MST therapy without GVHD…
- Trial name
- NCT02461121
- Testing
- HLA mismatched stem cell, HLA matched stem cell, cyclosporine A
- Where
- China
- Volunteers
- 156 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Acute Promyelocytic Leukemia
Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia
The therapeutic advantage of the association of ATRA + Arsenic Trioxide is more favorable and manageable as compared to ATRA + chemotherapy.
- Trial name
- APL0618 (NCT03751917)
- Testing
- Arsenic Trioxide
- Where
- 28 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia
This is a Phase I trial investigating the safety of using thioridazine in addition to cytarabine in elderly patients with relapsed or refractory Acute Myeloid Leukemia.
- Trial name
- THORIDAL (NCT02096289)
- Testing
- Thioridazine
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
AML, MDS
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
This is a randomized, open-label, multicenter study to compare the efficacy and safety of AZA with or without ATRA in newly diagnosed unfit AML or Intermediate,High or Very High Risk MDS
- Conditions
- AML, MDS, Old Age; Debility, Hematologic Cancer
- Trial name
- NCT05175508
- Testing
- Azacitidine, all trans retinoic acid
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia
VA Consolidation in Intermediate-Risk AML
This clinical trial aims to compare the efficacy and safety of venetoclax-based consolidation therapy versus conventional consolidation chemotherapy (intermediate/high-dose cytarabine) in newly diagnosed adult patients with…
- Conditions
- Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy
- Trial name
- NCT07672262
- Testing
- Venetoclax and Azacitidine, Cytarabine ± Anthracycline
- Where
- China
- Volunteers
- 226 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia (AML), Elderly
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the Elderly
- Trial name
- NCT06990321
- Testing
- Intermediate-dose Cytarabine in Combination with Venetoclax
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Yehui Tan
Acute Myeloid Leukemia
The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)
This study is a phase II randomized multicenter study. Patients will be enrolled at time of diagnosis and will receive one or two cycles of induction chemotherapy.
- Trial name
- CLARA (NCT00932412)
- Testing
- CLARA, HDAc
- Where
- 34 sites in France
- Volunteers
- 735 people
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute…
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT02085408
- Testing
- Daunorubicin, Cytarabine, Clofarabine
- Where
- 269 sites in United States, India and 1 more
- Volunteers
- 727 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Leukemia
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003758
- Testing
- cytarabine, idarubicin, allogeneic bone marrow transplantation
- Where
- 16 sites in Belgium, Croatia and 5 more
- Volunteers
- 60 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML
Create a network of institutions in developing countries that will perform AML diagnosis, risk classification, treatment, supportive care and follow-up evaluation according to a common protocol and will register data using common…
- Trial name
- ICAML2015 (NCT03023384)
- Where
- 6 sites in Brazil
- Volunteers
- 547 people
- Sponsor
- International Consortium on Acute Leukemias
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
The main part of this trial is a phase II study of vosaroxin with azacitidine in older patients with newly diagnosed AML and intermediate or adverse genetic risk or MDS-EB-2.
- Trial name
- NCT03338348
- Testing
- Vosaroxin, Azacitidine
- Where
- 3 sites in Germany
- Volunteers
- 9 people
- Sponsor
- University of Ulm
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
This phase I/II trial studies the side effects and best dose of guadecitabine when given together with atezolizumab and to see how well they work in treating patients with myelodysplastic syndrome or chronic myelomonocytic…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Trial name
- NCT02935361
- Testing
- Atezolizumab, Guadecitabine
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Southern California
MDS, CMML
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Phase 1-2 dose-escalation randomized study in participants with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML).
- Conditions
- MDS, CMML, AML
- Trial name
- NCT01261312
- Testing
- Guadecitabine
- Where
- 16 sites in United States, Canada
- Volunteers
- 414 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission
This phase II trial studies how well donor cellular therapy after cytarabine works in treating patients with intermediate-risk acute myeloid leukemia with a decrease in or disappearance of signs and symptoms of cancer.
- Trial name
- NCT02587871
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Sponsor
- University of Southern California